Metavention raises $65m to tackle diabetes with metabolic neuromodulation therapy

Metavention said today that it closed a $65 million Series C round with funding from New Enterprise Associates, Sanderling Ventures and others.

The medical device maker plans to use the funds to optimize its transcatheter-based metabolic neuromodulation therapy for people with Type II diabetes and prepare it for a Phase II trial in the U.S.

Get the full story at our sister site, Drug Delivery Business News.

The post Metavention raises $65m to tackle diabetes with metabolic neuromodulation therapy appeared first on MassDevice.

from MassDevice http://ift.tt/2CY9Fms